C22 Glucosylceramide (d18:1/22:0) (Synonyms: N-C22:0-Glucocerebroside, C22 Glucosylceramide, GluCer(18:1/22:0), Glucosylceramide (d18:1/22:0, N-Docosanoyl-β-glucosylsphingosine, N-Docosanoyl-glucopsychosine) |
Catalog No.GC43070 |
C22 Glucosylceramide (d18:1/22:0) is an endogenous glucosylceramide.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 119242-44-3
Sample solution is provided at 25 µL, 10mM.
C22 Glucosylceramide (d18:1/22:0) is an endogenous glucosylceramide. Glucosylceramides are major constituents of skin lipid membranes where they play a role in maintaining the water permeability barrier. They are precursors in the synthesis of lactosylceramide , as well as oligoglycolipids and gangliosides. Phospholipase A2 (PLA2) type XIIA knockdown increases C22 glucosylceramide (d18:1/22:0) expression in rat brain. It is also increased in the brain, but not the liver or spinal cord, of mice fed a methionine-restricted diet. In human athletes, plasma levels of C22 glucosylceramide (d18:1/22:0) increase during exercise and return to basal levels during recovery. This product contains C22 glucosylceramide (d18:1/22:0) isolated from bovine buttermilk.
Average Rating: 5
(Based on Reviews and 37 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *